Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder

摘要: The aim of this study was to compare the efficacy and tolerability reboxetine, a uniquely selective noradrenaline reuptake inhibitor, with serotonin fluoxetine. A double-blind, randomized, parallel-group, multicentre design employed. One hundred sixty-eight patients acute major depressive episodes were randomized receive oral reboxetine (8-10 mg/day) or fluoxetine (20-40 mg/day). treatment period 8 weeks. Reboxetine similarly effective as assessed by mean reduction in total Hamilton Depression Rating Scale score, percentage responders remission, Clinical Global Impression severity illness global improvement scores Montgomery-Asberg Scale. sub-analysis severe depression indicated that had superior compared Both treatments resulted some Social Adaptation Self-evaluation more evident for those treated who achieved remission. well tolerated. results indicate is an tolerated antidepressant, being than depression, terms social functioning